Quantum Biopharma (QNTM) EBITDA (2019 - 2026)

Quantum Biopharma (QNTM) has 8 years of EBITDA data on file, last reported at -$13.6 million in Q1 2026.

• Quarterly EBITDA fell 55.9% year-over-year to -$13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.3 million (down 72.55% YoY) and the FY2025 annual result came in at -$15.3 million, up 5.17% from the prior year.
• EBITDA fell to -$13.6 million in Q1 2026 per QNTM's latest filing, from -$2.4 million in the prior quarter.
• The five-year high for EBITDA was $6.0 million in Q1 2022, with the low at -$13.6 million in Q1 2026.
• Average EBITDA over 5 years is -$4.6 million, with a median of -$3.4 million recorded in 2024.
• The widest YoY moves for EBITDA: up 76.62% in 2024, down 278.05% in 2024.
• Quantum Biopharma's EBITDA stood at $6.0 million in 2022, then plunged by 114.45% to -$863852.0 in 2023, then plunged by 142.1% to -$2.1 million in 2024, then decreased by 13.48% to -$2.4 million in 2025, then sank by 474.31% to -$13.6 million in 2026.
• Business Quant data shows QNTM's EBITDA at -$13.6 million in Q1 2026, -$2.4 million in Q4 2025, and -$4.6 million in Q3 2025.